828 related articles for article (PubMed ID: 28221817)
1. Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase.
Mori MA; Delattre AM; Carabelli B; Pudell C; Bortolanza M; Staziaki PV; Visentainer JV; Montanher PF; Del Bel EA; Ferraz AC
Nutr Neurosci; 2018 Jun; 21(5):341-351. PubMed ID: 28221817
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glycogen synthase kinase-3β by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes.
Wang HM; Zhang T; Li Q; Huang JK; Chen RF; Sun XJ
Neurochem Int; 2013 Nov; 63(5):345-53. PubMed ID: 23871716
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease.
Ojha S; Javed H; Azimullah S; Abul Khair SB; Haque ME
Drug Des Devel Ther; 2015; 9():5499-510. PubMed ID: 26504373
[TBL] [Abstract][Full Text] [Related]
4. Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson's Disease.
Jayaraj RL; Beiram R; Azimullah S; Meeran MFN; Ojha SK; Adem A; Jalal FY
Molecules; 2019 Jun; 24(11):. PubMed ID: 31185705
[TBL] [Abstract][Full Text] [Related]
5. Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.
Singh S; Mishra A; Srivastava N; Shukla R; Shukla S
Mol Neurobiol; 2018 Jan; 55(1):583-602. PubMed ID: 27975173
[TBL] [Abstract][Full Text] [Related]
6. Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model.
Tentillier N; Etzerodt A; Olesen MN; Rizalar FS; Jacobsen J; Bender D; Moestrup SK; Romero-Ramos M
J Neurosci; 2016 Sep; 36(36):9375-90. PubMed ID: 27605613
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease.
Giuliano C; Siani F; Mus L; Ghezzi C; Cerri S; Pacchetti B; Bigogno C; Blandini F
Nutrition; 2020 Jan; 69():110494. PubMed ID: 31586482
[TBL] [Abstract][Full Text] [Related]
8. The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.
Baluchnejadmojarad T; Eftekhari SM; Jamali-Raeufy N; Haghani S; Zeinali H; Roghani M
Exp Gerontol; 2017 Dec; 100():70-76. PubMed ID: 29107062
[TBL] [Abstract][Full Text] [Related]
9. Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.
Chen HH; Chang PC; Chen C; Chan MH
Pharmacol Rep; 2018 Aug; 70(4):668-676. PubMed ID: 29909247
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
11. A bibenzyl compound 20C protects rats against 6-OHDA-induced damage by regulating adaptive immunity associated molecules.
Wang S; Han QW; Zhou TT; Zhang CL; Zhu CG; Zhou X; Chen NH; Yuan YH; Shi JG
Int Immunopharmacol; 2021 Feb; 91():107269. PubMed ID: 33340781
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of trans-cinnamaldehyde on the 6-hydroxydopamine-induced dopaminergic injury.
Pyo JH; Jeong YK; Yeo S; Lee JH; Jeong MY; Kim SH; Choi YG; Lim S
Biol Pharm Bull; 2013; 36(12):1928-35. PubMed ID: 24292051
[TBL] [Abstract][Full Text] [Related]
13. ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
Singh S; Mishra A; Shukla S
Mol Neurobiol; 2016 Sep; 53(7):4286-301. PubMed ID: 26223802
[TBL] [Abstract][Full Text] [Related]
14. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
15. A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).
Smith GA; Rocha EM; Rooney T; Barneoud P; McLean JR; Beagan J; Osborn T; Coimbra M; Luo Y; Hallett PJ; Isacson O
PLoS One; 2015; 10(3):e0121072. PubMed ID: 25815475
[TBL] [Abstract][Full Text] [Related]
16. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y.
Pain S; Vergote J; Gulhan Z; Bodard S; Chalon S; Gaillard A
Fundam Clin Pharmacol; 2019 Oct; 33(5):544-548. PubMed ID: 30866091
[TBL] [Abstract][Full Text] [Related]
19. Valeric Acid Protects Dopaminergic Neurons by Suppressing Oxidative Stress, Neuroinflammation and Modulating Autophagy Pathways.
Jayaraj RL; Beiram R; Azimullah S; Mf NM; Ojha SK; Adem A; Jalal FY
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081327
[TBL] [Abstract][Full Text] [Related]
20. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
